ID   ENOA_HUMAN              Reviewed;         434 AA.
AC   P06733; B2RD59; P22712; Q16704; Q4TUS4; Q53FT9; Q53HR3; Q658M5;
AC   Q6GMP2; Q71V37; Q7Z3V6; Q8WU71; Q96GV1; Q9BT62; Q9UCH6; Q9UM55;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 212.
DE   RecName: Full=Alpha-enolase;
DE            EC=4.2.1.11;
DE   AltName: Full=2-phospho-D-glycerate hydro-lyase;
DE   AltName: Full=C-myc promoter-binding protein;
DE   AltName: Full=Enolase 1;
DE   AltName: Full=MBP-1;
DE   AltName: Full=MPB-1;
DE   AltName: Full=Non-neural enolase;
DE            Short=NNE;
DE   AltName: Full=Phosphopyruvate hydratase;
DE   AltName: Full=Plasminogen-binding protein;
GN   Name=ENO1; Synonyms=ENO1L1, MBPB1, MPB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE).
RX   PubMed=3529090; DOI=10.1073/pnas.83.18.6741;
RA   Giallongo A., Feo S., Moore R., Croce C.M., Showe L.C.;
RT   "Molecular cloning and nucleotide sequence of a full-length cDNA for
RT   human alpha enolase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6741-6745(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=T-cell;
RX   PubMed=2373081; DOI=10.1111/j.1432-1033.1990.tb15611.x;
RA   Giallongo A., Oliva D., Cali L., Barba G., Barbieri G., Feo S.;
RT   "Structure of the human gene for alpha-enolase.";
RL   Eur. J. Biochem. 190:567-573(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MBP-1), AND FUNCTION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=2005901; DOI=10.1128/MCB.11.4.2154;
RA   Ray R., Miller D.M.;
RT   "Cloning and characterization of a human c-myc promoter-binding
RT   protein.";
RL   Mol. Cell. Biol. 11:2154-2161(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE), AND MARKER FOR
RP   ENDOMETRIOSIS.
RC   TISSUE=Endometrium;
RX   PubMed=8824716; DOI=10.1016/S0896-8411(95)80027-1;
RA   Walter M., Berg H., Leidenberger F.A., Schweppe K.W., Northemann W.;
RT   "Autoreactive epitopes within the human alpha-enolase and their
RT   recognition by sera from patients with endometriosis.";
RL   J. Autoimmun. 8:931-945(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Adipose tissue, and Kidney proximal tubule;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Retina, and Stomach;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-177.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Brain, Eye, Lung, Ovary, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-9 (ISOFORM ALPHA-ENOLASE).
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-28; 65-80; 121-162; 234-253; 270-281; 331-394
RP   AND 407-420, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Lilla S., Zebisch A., Kolch W.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 16-28; 33-50; 93-103; 106-120; 163-179; 184-193;
RP   203-221; 240-253; 257-262; 270-281; 286-326; 336-394 AND 407-412, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 166-434.
RX   PubMed=9653645; DOI=10.1006/geno.1997.5186;
RA   Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
RT   "Molecular cloning and expression analysis of five novel genes in
RT   chromosome 1p36.";
RL   Genomics 50:187-198(1998).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 171-434.
RC   TISSUE=Brain;
RX   PubMed=9110174;
RA   Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
RA   Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
RT   "Large-scale concatenation cDNA sequencing.";
RL   Genome Res. 7:353-358(1997).
RN   [18]
RP   PROTEIN SEQUENCE OF 203-228, FUNCTION, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RC   TISSUE=Lymphoma;
RX   PubMed=1369209; DOI=10.1007/BF00570890;
RA   Sugahara T., Nakajima H., Shirahata S., Murakami H.;
RT   "Purification and characterization of immunoglobulin production
RT   stimulating factor-II beta derived from Namalwa cells.";
RL   Cytotechnology 10:137-146(1992).
RN   [19]
RP   PROTEIN SEQUENCE OF 270-281 AND 307-321, AND INDUCTION IN DIFFUSE
RP   LARGE CELL LYMPHOMA.
RX   PubMed=7787969;
RA   Mohamad R.M., Hamdan M.Y., Maki A., Al-Katib A.;
RT   "Induced expression of alpha-enolase in differentiated diffuse large
RT   cell lymphoma.";
RL   Enzyme Protein 48:37-44(1994).
RN   [20]
RP   FUNCTION OF MBP1, IDENTIFICATION OF REPRESSOR DOMAINS, AND MUTAGENESIS
RP   OF LEU-384 AND LEU-388.
RX   PubMed=10082554; DOI=10.1128/MCB.19.4.2880;
RA   Ghosh A.K., Steele R., Ray R.B.;
RT   "Functional domains of c-myc promoter binding protein 1 involved in
RT   transcriptional repression and cell growth regulation.";
RL   Mol. Cell. Biol. 19:2880-2886(1999).
RN   [21]
RP   FUNCTION AS A C-MYC TRANSCRIPTIONAL REPRESSOR, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10802057; DOI=10.1016/S0014-5793(00)01494-0;
RA   Feo S., Arcuri D., Piddini E., Passantino R., Giallongo A.;
RT   "ENO1 gene product binds to the c-myc promoter and acts as a
RT   transcriptional repressor: relationship with Myc promoter-binding
RT   protein 1 (MBP-1).";
RL   FEBS Lett. 473:47-52(2000).
RN   [22]
RP   FUNCTION IN PLASMINOGEN ACTIVATION.
RX   PubMed=12666133; DOI=10.1002/ajh.10299;
RA   Lopez-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fabregas P.,
RA   Jardi M., Merton E., Miles L.A., Felez J.;
RT   "Inhibition of cell surface mediated plasminogen activation by a
RT   monoclonal antibody against alpha-enolase.";
RL   Am. J. Hematol. 72:234-242(2003).
RN   [23]
RP   INTERACTION WITH PLG.
RX   PubMed=9308760;
RA   Arza B., Felez J., Lopez-Alemany R., Miles L.A., Munoz-Canoves P.;
RT   "Identification of an epitope of alpha-enolase (a candidate
RT   plasminogen receptor) by phage display.";
RL   Thromb. Haemost. 78:1097-1103(1997).
RN   [24]
RP   EPITOPE MAPPING, AND ASSOCIATION WITH CAR.
RX   PubMed=9878089; DOI=10.1006/jaut.1998.0239;
RA   Adamus G., Amundson D., Seigel G.M., Machnicki M.;
RT   "Anti-enolase-alpha autoantibodies in cancer-associated retinopathy:
RT   epitope mapping and cytotoxicity on retinal cells.";
RL   J. Autoimmun. 11:671-677(1998).
RN   [25]
RP   IDENTIFICATION OF MBP1 AS AN ALPHA-ENOLASE ALTERNATIVE INITIATION
RP   PRODUCT, AND MUTAGENESIS OF MET-94 AND MET-97.
RX   PubMed=10681589; DOI=10.1074/jbc.275.8.5958;
RA   Subramanian A., Miller D.M.;
RT   "Structural analysis of alpha-enolase. Mapping the functional domains
RT   involved in down-regulation of the c-myc protooncogene.";
RL   J. Biol. Chem. 275:5958-5965(2000).
RN   [26]
RP   REVIEW.
RX   PubMed=11497239; DOI=10.1007/PL00000910;
RA   Pancholi V.;
RT   "Multifunctional alpha-enolase: its role in diseases.";
RL   Cell. Mol. Life Sci. 58:902-920(2001).
RN   [27]
RP   INTERACTION WITH TRAPPC2B (ISOFORM MBP-1).
RX   PubMed=11134351; DOI=10.1128/MCB.21.2.655-662.2001;
RA   Ghosh A.K., Majumder M., Steele R., White R.A., Ray R.B.;
RT   "A novel 16-kilodalton cellular protein physically interacts with and
RT   antagonizes the functional activity of c-myc promoter-binding protein
RT   1.";
RL   Mol. Cell. Biol. 21:655-662(2001).
RN   [28]
RP   IDENTIFICATION AS AN AUTOANTIGEN IN HASHIMOTO ENCEPHALOPATHY.
RX   PubMed=12297304; DOI=10.1016/S0014-5793(02)03307-0;
RA   Ochi H., Horiuchi I., Araki N., Toda T., Araki T., Sato K., Murai H.,
RA   Osoegawa M., Yamada T., Okamura K., Ogino T., Mizumoto K.,
RA   Yamashita H., Saya H., Kira J.;
RT   "Proteomic analysis of human brain identifies alpha-enolase as a novel
RT   autoantigen in Hashimoto's encephalopathy.";
RL   FEBS Lett. 528:197-202(2002).
RN   [29]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-44 AND TYR-287, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [31]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
RT   reveal differential cellular gene expression in response to
RT   enterovirus 71 infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [32]
RP   ISGYLATION.
RX   PubMed=16815975; DOI=10.1073/pnas.0600397103;
RA   Wong J.J., Pung Y.F., Sze N.S., Chin K.C.;
RT   "HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates
RT   type I IFN-induced ISGylation of protein targets.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10735-10740(2006).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254 AND SER-263, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-5; LYS-64; LYS-71; LYS-89;
RP   LYS-126; LYS-193; LYS-199; LYS-228; LYS-233; LYS-256; LYS-281; LYS-285
RP   AND LYS-420, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   MALONYLATION AT LYS-233 AND LYS-420.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-254; SER-263 AND
RP   SER-272, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-291, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2-434, SUBUNIT, COFACTOR, AND
RP   METAL-BINDING SITES.
RX   PubMed=18560153; DOI=10.1107/S0907444908008561;
RA   Kang H.J., Jung S.K., Kim S.J., Chung S.J.;
RT   "Structure of human alpha-enolase (hENO1), a multifunctional
RT   glycolytic enzyme.";
RL   Acta Crystallogr. D 64:651-657(2008).
CC   -!- FUNCTION: Multifunctional enzyme that, as well as its role in
CC       glycolysis, plays a part in various processes such as growth
CC       control, hypoxia tolerance and allergic responses. May also
CC       function in the intravascular and pericellular fibrinolytic system
CC       due to its ability to serve as a receptor and activator of
CC       plasminogen on the cell surface of several cell-types such as
CC       leukocytes and neurons. Stimulates immunoglobulin production.
CC   -!- FUNCTION: MBP1 binds to the myc promoter and acts as a
CC       transcriptional repressor. May be a tumor suppressor.
CC   -!- CATALYTIC ACTIVITY: 2-phospho-D-glycerate = phosphoenolpyruvate +
CC       H(2)O. {ECO:0000269|PubMed:1369209}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:18560153};
CC       Note=Binds two Mg(2+) per subunit. Required for catalysis and for
CC       stabilizing the dimer. {ECO:0000269|PubMed:18560153};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Enolase activity is lost above pH 9.0. Immunoglobulin production
CC         stimulating activity is retained at pH 13.0.
CC         {ECO:0000269|PubMed:1369209};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 4/5.
CC   -!- SUBUNIT: Mammalian enolase is composed of 3 isozyme subunits,
CC       alpha, beta and gamma, which can form homodimers or heterodimers
CC       which are cell-type and development-specific (PubMed:18560153).
CC       ENO1 interacts with PLG in the neuronal plasma membrane and
CC       promotes its activation. The C-terminal lysine is required for
CC       this binding (PubMed:9308760). Isoform MBP-1 interacts with
CC       TRAPPC2B (PubMed:11134351). Interacts with ENO4 and PGAM2 (By
CC       similarity). {ECO:0000250|UniProtKB:P17182,
CC       ECO:0000269|PubMed:11134351, ECO:0000269|PubMed:18560153,
CC       ECO:0000269|PubMed:9308760}.
CC   -!- INTERACTION:
CC       P22303:ACHE; NbExp=2; IntAct=EBI-353877, EBI-1637793;
CC       Q60823:Akt2 (xeno); NbExp=2; IntAct=EBI-353877, EBI-400263;
CC       P12004:PCNA; NbExp=3; IntAct=EBI-353877, EBI-358311;
CC       Q8WZ42:TTN; NbExp=3; IntAct=EBI-353877, EBI-681210;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-353877, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10802057}.
CC       Cell membrane {ECO:0000269|PubMed:10802057}. Cytoplasm, myofibril,
CC       sarcomere, M line {ECO:0000269|PubMed:10802057}. Note=Can
CC       translocate to the plasma membrane in either the homodimeric
CC       (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is
CC       localized to the M line.
CC   -!- SUBCELLULAR LOCATION: Isoform MBP-1: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=alpha-enolase;
CC         IsoId=P06733-1; Sequence=Displayed;
CC       Name=MBP-1;
CC         IsoId=P06733-2; Sequence=VSP_018725;
CC         Note=It is uncertain whether the alternative initiation site is
CC         at Met-94 or at Met-97.;
CC   -!- TISSUE SPECIFICITY: The alpha/alpha homodimer is expressed in
CC       embryo and in most adult tissues. The alpha/beta heterodimer and
CC       the beta/beta homodimer are found in striated muscle, and the
CC       alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.
CC   -!- DEVELOPMENTAL STAGE: During ontogenesis, there is a transition
CC       from the alpha/alpha homodimer to the alpha/beta heterodimer in
CC       striated muscle cells, and to the alpha/gamma heterodimer in nerve
CC       cells.
CC   -!- INDUCTION: Induced in diffuse large cell lymphoma (DLCL) after
CC       treatment with the natural biological agent, Bryo1. Up-regulated
CC       in response to enterovirus 71 (EV71) infection (at protein level).
CC       {ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:7787969}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798,
CC       ECO:0000269|PubMed:16815975}.
CC   -!- MISCELLANEOUS: Used as a diagnostic marker for many tumors and, in
CC       the heterodimeric form, alpha/gamma, as a marker for hypoxic brain
CC       injury after cardiac arrest. Also marker for endometriosis.
CC       Antibodies against alpha-enolase are present in sera from patients
CC       with cancer-associated retinopathy syndrome (CAR), a progressive
CC       blinding disease which occurs in the presence of systemic tumor
CC       growth, primarily small-cell carcinoma of the lung and other
CC       malignancies. Is identified as an autoantigen in Hashimoto
CC       encephalopathy (HE) a rare autoimmune disease associated with
CC       Hashimoto thyroiditis (HT). HT is a disorder in which destructive
CC       processes overcome the potential capacity of thyroid replacement
CC       leading to hypothyroidism.
CC   -!- SIMILARITY: Belongs to the enolase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35698.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC       Sequence=AAA35698.1; Type=Miscellaneous discrepancy; Note=Sequencing errors.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/eno1/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ENO1ID40453ch1p36.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14328; AAA52387.1; -; mRNA.
DR   EMBL; X16288; CAA34360.1; -; Genomic_DNA.
DR   EMBL; X16289; CAA34360.1; JOINED; Genomic_DNA.
DR   EMBL; X16290; CAA34360.1; JOINED; Genomic_DNA.
DR   EMBL; M55914; AAA35698.1; ALT_FRAME; mRNA.
DR   EMBL; X84907; CAA59331.1; -; mRNA.
DR   EMBL; BT007163; AAP35827.1; -; mRNA.
DR   EMBL; AK315417; BAG37806.1; -; mRNA.
DR   EMBL; AL833741; CAH56247.1; -; mRNA.
DR   EMBL; BX537400; CAD97642.1; -; mRNA.
DR   EMBL; AK222517; BAD96237.1; -; mRNA.
DR   EMBL; AK223192; BAD96912.1; -; mRNA.
DR   EMBL; DQ056744; AAY43128.1; -; Genomic_DNA.
DR   EMBL; AL139415; CAC42425.1; -; Genomic_DNA.
DR   EMBL; CH471130; EAW71604.1; -; Genomic_DNA.
DR   EMBL; BC001810; AAH01810.1; -; mRNA.
DR   EMBL; BC004325; AAH04325.1; -; mRNA.
DR   EMBL; BC004458; AAH04458.1; -; mRNA.
DR   EMBL; BC009218; AAH09218.2; -; mRNA.
DR   EMBL; BC009912; AAH09912.1; -; mRNA.
DR   EMBL; BC011130; AAH11130.1; -; mRNA.
DR   EMBL; BC015641; AAH15641.1; -; mRNA.
DR   EMBL; BC021166; AAH21166.2; -; mRNA.
DR   EMBL; BC022545; AAH22545.1; -; mRNA.
DR   EMBL; BC027725; AAH27725.1; -; mRNA.
DR   EMBL; BC050642; AAH50642.1; -; mRNA.
DR   EMBL; U88968; AAC39935.1; -; mRNA.
DR   EMBL; AF035286; AAB88178.1; -; mRNA.
DR   CCDS; CCDS97.1; -. [P06733-1]
DR   PIR; A39579; A39579.
DR   PIR; S11696; A29170.
DR   RefSeq; NP_001188412.1; NM_001201483.1. [P06733-2]
DR   RefSeq; NP_001419.1; NM_001428.3. [P06733-1]
DR   UniGene; Hs.517145; -.
DR   PDB; 2PSN; X-ray; 2.20 A; A/B/C/D=1-434.
DR   PDB; 3B97; X-ray; 2.20 A; A/B/C/D=2-434.
DR   PDB; 5JLZ; X-ray; 1.99 A; E/F=26-40.
DR   PDB; 5LAX; X-ray; 2.60 A; E/F=26-40.
DR   PDBsum; 2PSN; -.
DR   PDBsum; 3B97; -.
DR   PDBsum; 5JLZ; -.
DR   PDBsum; 5LAX; -.
DR   ProteinModelPortal; P06733; -.
DR   SMR; P06733; -.
DR   BioGrid; 108338; 284.
DR   IntAct; P06733; 83.
DR   MINT; MINT-155303; -.
DR   STRING; 9606.ENSP00000234590; -.
DR   BindingDB; P06733; -.
DR   ChEMBL; CHEMBL3298; -.
DR   iPTMnet; P06733; -.
DR   PhosphoSitePlus; P06733; -.
DR   SwissPalm; P06733; -.
DR   BioMuta; ENO1; -.
DR   DMDM; 119339; -.
DR   DOSAC-COBS-2DPAGE; P06733; -.
DR   OGP; P06733; -.
DR   REPRODUCTION-2DPAGE; IPI00465248; -.
DR   REPRODUCTION-2DPAGE; P06733; -.
DR   SWISS-2DPAGE; P06733; -.
DR   UCD-2DPAGE; P06733; -.
DR   EPD; P06733; -.
DR   MaxQB; P06733; -.
DR   PaxDb; P06733; -.
DR   PeptideAtlas; P06733; -.
DR   PRIDE; P06733; -.
DR   TopDownProteomics; P06733-1; -. [P06733-1]
DR   TopDownProteomics; P06733-2; -. [P06733-2]
DR   DNASU; 2023; -.
DR   Ensembl; ENST00000234590; ENSP00000234590; ENSG00000074800. [P06733-1]
DR   GeneID; 2023; -.
DR   KEGG; hsa:2023; -.
DR   UCSC; uc001apj.3; human. [P06733-1]
DR   CTD; 2023; -.
DR   DisGeNET; 2023; -.
DR   GeneCards; ENO1; -.
DR   HGNC; HGNC:3350; ENO1.
DR   HPA; CAB018614; -.
DR   HPA; CAB069394; -.
DR   HPA; HPA068284; -.
DR   MIM; 172430; gene.
DR   neXtProt; NX_P06733; -.
DR   OpenTargets; ENSG00000074800; -.
DR   PharmGKB; PA27786; -.
DR   eggNOG; KOG2670; Eukaryota.
DR   eggNOG; COG0148; LUCA.
DR   GeneTree; ENSGT00840000129817; -.
DR   HOVERGEN; HBG000067; -.
DR   InParanoid; P06733; -.
DR   KO; K01689; -.
DR   OMA; NFRNPRI; -.
DR   OrthoDB; EOG091G07NH; -.
DR   PhylomeDB; P06733; -.
DR   TreeFam; TF300391; -.
DR   BioCyc; MetaCyc:ENSG00000074800-MONOMER; -.
DR   BRENDA; 4.2.1.11; 2681.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P06733; -.
DR   SIGNOR; P06733; -.
DR   UniPathway; UPA00109; UER00187.
DR   ChiTaRS; ENO1; human.
DR   EvolutionaryTrace; P06733; -.
DR   GeneWiki; Alpha-enolase; -.
DR   GenomeRNAi; 2023; -.
DR   PMAP-CutDB; P06733; -.
DR   PRO; PR:P06733; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000074800; -.
DR   ExpressionAtlas; P06733; baseline and differential.
DR   Genevisible; P06733; HS.
DR   GO; GO:0099738; C:cell cortex region; IDA:CAFA.
DR   GO; GO:0009986; C:cell surface; IDA:CAFA.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000015; C:phosphopyruvate hydratase complex; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; IDA:CAFA.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004634; F:phosphopyruvate hydratase activity; IMP:CAFA.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:CAFA.
DR   GO; GO:0061621; P:canonical glycolysis; IMP:CAFA.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:1903298; P:negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway; IDA:CAFA.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:CAFA.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:2001171; P:positive regulation of ATP biosynthetic process; IDA:CAFA.
DR   GO; GO:0045933; P:positive regulation of muscle contraction; IGI:CAFA.
DR   GO; GO:0010756; P:positive regulation of plasminogen activation; IMP:CAFA.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd03313; enolase; 1.
DR   Gene3D; 3.20.20.120; -; 1.
DR   Gene3D; 3.30.390.10; -; 1.
DR   HAMAP; MF_00318; Enolase; 1.
DR   InterPro; IPR000941; Enolase.
DR   InterPro; IPR034390; Enolase-like_superfamily.
DR   InterPro; IPR020810; Enolase_C.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR020809; Enolase_CS.
DR   InterPro; IPR020811; Enolase_N.
DR   InterPro; IPR029017; Enolase_N-like.
DR   PANTHER; PTHR11902; PTHR11902; 1.
DR   Pfam; PF00113; Enolase_C; 1.
DR   Pfam; PF03952; Enolase_N; 1.
DR   PIRSF; PIRSF001400; Enolase; 1.
DR   PRINTS; PR00148; ENOLASE.
DR   SFLD; SFLDG00178; enolase; 1.
DR   SFLD; SFLDS00001; Enolase; 1.
DR   SMART; SM01192; Enolase_C; 1.
DR   SMART; SM01193; Enolase_N; 1.
DR   SUPFAM; SSF51604; SSF51604; 1.
DR   SUPFAM; SSF54826; SSF54826; 1.
DR   TIGRFAMs; TIGR01060; eno; 1.
DR   PROSITE; PS00164; ENOLASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; DNA-binding;
KW   Glycolysis; Lyase; Magnesium; Membrane; Metal-binding; Nucleus;
KW   Phosphoprotein; Plasminogen activation; Polymorphism;
KW   Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.14}.
FT   CHAIN         2    434       Alpha-enolase.
FT                                /FTId=PRO_0000134097.
FT   REGION       31     38       Epitope recognized by CAR and healthy
FT                                patient antibodies.
FT   REGION       56     63       Epitope recognized by CAR antibodies.
FT   REGION       97    237       Required for repression of c-myc promoter
FT                                activity.
FT   REGION      370    373       Substrate binding. {ECO:0000250}.
FT   REGION      405    434       Required for interaction with PLG.
FT                                {ECO:0000250}.
FT   ACT_SITE    210    210       Proton donor. {ECO:0000250}.
FT   ACT_SITE    343    343       Proton acceptor. {ECO:0000250}.
FT   METAL        40     40       Magnesium 1.
FT   METAL       245    245       Magnesium 2.
FT   METAL       293    293       Magnesium 2.
FT   METAL       318    318       Magnesium 2.
FT   BINDING     158    158       Substrate. {ECO:0000250}.
FT   BINDING     167    167       Substrate. {ECO:0000250}.
FT   BINDING     293    293       Substrate. {ECO:0000250}.
FT   BINDING     318    318       Substrate. {ECO:0000250}.
FT   BINDING     394    394       Substrate. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:25944712,
FT                                ECO:0000269|Ref.14}.
FT   MOD_RES       5      5       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      44     44       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES      60     60       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES      60     60       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES      64     64       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      71     71       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      89     89       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      89     89       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES      92     92       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     126    126       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     193    193       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     199    199       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     202    202       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     228    228       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     228    228       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     233    233       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     233    233       N6-malonyllysine; alternate.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     254    254       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     256    256       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     263    263       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     272    272       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     281    281       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     285    285       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     287    287       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     291    291       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     335    335       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     343    343       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     406    406       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   MOD_RES     420    420       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     420    420       N6-malonyllysine; alternate.
FT                                {ECO:0000269|PubMed:21908771}.
FT   MOD_RES     420    420       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P17182}.
FT   VAR_SEQ       1     93       Missing (in isoform MBP-1).
FT                                {ECO:0000303|PubMed:2005901}.
FT                                /FTId=VSP_018725.
FT   VARIANT     177    177       N -> K (in dbSNP:rs11544513).
FT                                {ECO:0000269|Ref.9}.
FT                                /FTId=VAR_025172.
FT   VARIANT     325    325       P -> Q (in dbSNP:rs11544514).
FT                                /FTId=VAR_048936.
FT   MUTAGEN      94     94       M->I: MBP1 protein production. No MBP1
FT                                protein production; when associated with
FT                                I-97. {ECO:0000269|PubMed:10681589}.
FT   MUTAGEN      97     97       M->I: MBP1 protein production. No MBP1
FT                                protein production; when associated with
FT                                I-94. {ECO:0000269|PubMed:10681589}.
FT   MUTAGEN     384    384       L->A: Loss of transcriptional repression
FT                                and cell growth inhibition; when
FT                                associated with A-388.
FT                                {ECO:0000269|PubMed:10082554}.
FT   MUTAGEN     388    388       L->A: Loss of transcriptional repression
FT                                and cell growth inhibition; when
FT                                associated with A-384.
FT                                {ECO:0000269|PubMed:10082554}.
FT   CONFLICT     55     55       T -> A (in Ref. 8; CAD97642).
FT                                {ECO:0000305}.
FT   CONFLICT     78     78       V -> A (in Ref. 7; BAD96237).
FT                                {ECO:0000305}.
FT   CONFLICT    187    187       E -> G (in Ref. 8; CAD97642).
FT                                {ECO:0000305}.
FT   CONFLICT    199    199       K -> R (in Ref. 7; BAD96912).
FT                                {ECO:0000305}.
FT   CONFLICT    252    252       F -> S (in Ref. 4; CAA59331).
FT                                {ECO:0000305}.
FT   CONFLICT    310    310       S -> I (in Ref. 8; CAD97642).
FT                                {ECO:0000305}.
FT   STRAND        5     12       {ECO:0000244|PDB:2PSN}.
FT   STRAND       18     26       {ECO:0000244|PDB:2PSN}.
FT   STRAND       29     34       {ECO:0000244|PDB:2PSN}.
FT   HELIX        57     59       {ECO:0000244|PDB:2PSN}.
FT   HELIX        63     71       {ECO:0000244|PDB:2PSN}.
FT   HELIX        73     79       {ECO:0000244|PDB:2PSN}.
FT   HELIX        87     98       {ECO:0000244|PDB:2PSN}.
FT   TURN        104    106       {ECO:0000244|PDB:2PSN}.
FT   HELIX       108    125       {ECO:0000244|PDB:2PSN}.
FT   HELIX       130    138       {ECO:0000244|PDB:2PSN}.
FT   STRAND      147    154       {ECO:0000244|PDB:2PSN}.
FT   HELIX       156    158       {ECO:0000244|PDB:2PSN}.
FT   STRAND      159    162       {ECO:0000244|PDB:2PSN}.
FT   STRAND      167    171       {ECO:0000244|PDB:2PSN}.
FT   HELIX       178    200       {ECO:0000244|PDB:2PSN}.
FT   HELIX       202    204       {ECO:0000244|PDB:2PSN}.
FT   HELIX       220    233       {ECO:0000244|PDB:2PSN}.
FT   TURN        237    239       {ECO:0000244|PDB:2PSN}.
FT   STRAND      241    245       {ECO:0000244|PDB:2PSN}.
FT   HELIX       248    250       {ECO:0000244|PDB:2PSN}.
FT   TURN        259    262       {ECO:0000244|PDB:2PSN}.
FT   HELIX       267    269       {ECO:0000244|PDB:2PSN}.
FT   HELIX       273    286       {ECO:0000244|PDB:2PSN}.
FT   STRAND      289    293       {ECO:0000244|PDB:2PSN}.
FT   HELIX       301    311       {ECO:0000244|PDB:2PSN}.
FT   STRAND      313    318       {ECO:0000244|PDB:2PSN}.
FT   TURN        319    323       {ECO:0000244|PDB:2PSN}.
FT   HELIX       325    334       {ECO:0000244|PDB:2PSN}.
FT   STRAND      338    342       {ECO:0000244|PDB:2PSN}.
FT   HELIX       344    347       {ECO:0000244|PDB:2PSN}.
FT   HELIX       350    362       {ECO:0000244|PDB:2PSN}.
FT   STRAND      366    370       {ECO:0000244|PDB:2PSN}.
FT   HELIX       380    387       {ECO:0000244|PDB:2PSN}.
FT   STRAND      391    394       {ECO:0000244|PDB:2PSN}.
FT   HELIX       401    417       {ECO:0000244|PDB:2PSN}.
FT   HELIX       418    420       {ECO:0000244|PDB:2PSN}.
FT   HELIX       425    427       {ECO:0000244|PDB:2PSN}.
SQ   SEQUENCE   434 AA;  47169 MW;  A0ED663FCC15ADA5 CRC64;
     MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR DNDKTRYMGK
     GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT ENKSKFGANA ILGVSLAVCK
     AGAVEKGVPL YRHIADLAGN SEVILPVPAF NVINGGSHAG NKLAMQEFMI LPVGAANFRE
     AMRIGAEVYH NLKNVIKEKY GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV
     VIGMDVAASE FFRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD
     WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV TESLQACKLA
     QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL LRIEEELGSK
     AKFAGRNFRN PLAK
//
